Search

Your search keyword '"Alex Duval"' showing total 429 results

Search Constraints

Start Over You searched for: Author "Alex Duval" Remove constraint Author: "Alex Duval"
429 results on '"Alex Duval"'

Search Results

1. Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiation

2. Pan-cancer landscape of AID-related mutations, composite mutations, and their potential role in the ICI response

3. Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer

4. Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite InstabilitySummary

5. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

6. MiRNA genes constitute new targets for microsatellite instability in colorectal cancer.

7. Nonsense-mediated mRNA decay impacts MSI-driven carcinogenesis and anti-tumor immunity in colorectal cancers.

8. Chromosomal instability in near-diploid colorectal cancer: a link between numbers and structure.

9. Cohort of HIV Associated Lymphomas (ANRS CO16)

10. RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status

11. Lynch syndrome: influence of additional susceptibility variants on cancer risk

12. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

13. Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

14. Supplementary Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

15. Lynch syndrome: influence of additional susceptibility variants on cancer risk

16. Prediction of Response to Immune Checkpoint Blockade in Patients with Metastatic Colorectal Cancer with Microsatellite Instability

17. Pan-cancer landscape of AID-related mutations, composite mutations, and their potential role in the ICI response

18. Mechanisms and therapeutic implications of hypermutation in gliomas

19. Patients atteints d’un cancer gastrique localisé MSI/dMMR, pas de chimiothérapie mais une immunothérapie périopératoire : l’essai de phase II GERCOR NEONIPIGA vient d’être ouvert au recrutement

20. Efficacy and tolerability of immune checkpoint inhibitors in elderly patients with MSI/dMMR gastrointestinal cancers and impact of toxicities on efficacy: The immunoMSI cohort

21. Impact of Lynch syndrome, BRAFV600E, and RAS mutations on outcomes in MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Analysis of combined international cohorts

22. Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice

23. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair

24. Instabilité des microsatellites et cancer

25. The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review

26. Pan-cancer landscape of AID-related mutations, composite mutations and its potential role in the ICI response

27. Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

28. Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency

29. MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review

30. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

31. Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer

32. Overcoming the challenges associated with universal screening for Lynch syndrome in colorectal and endometrial cancer

33. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

34. Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite Instability

35. Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives

36. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency

37. Immunotherapy and patients treated for cancer with microsatellite instability

38. DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS

39. OS9.1 Clinical significance of hypermutation in gliomas

40. Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome

41. [Microsatellite instability and cancer: from genomic instability to personalized medicine]

42. Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer-Beyond the Misdiagnosis-In Reply

43. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors

44. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCER

45. Low temperature isothermal amplification of microsatellites drastically reduces stutter artifact formation and improves microsatellite instability detection in cancer

46. Lynch syndrome: What is new?

47. Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer

48. Corrigendum to ‘Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study’

49. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR)

50. PATH-16. MOLECULAR PATHOLOGY AND CLINICAL CHARACTERISTICS OF MMR DEFICIENCY (MMRd) IN DIFFUSE GLIOMAS

Catalog

Books, media, physical & digital resources